Bruker (NASDAQ:BRKR) Director Cynthia Friend Sells 3,535 Shares

Bruker Corporation (NASDAQ:BRKR) Director Cynthia Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Bruker Stock Performance

NASDAQ:BRKR opened at $30.91 on Friday. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $72.94. The company has a fifty day simple moving average of $36.02 and a two-hundred day simple moving average of $38.90. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The company has a market cap of $4.69 billion, a price-to-earnings ratio of 59.44, a price-to-earnings-growth ratio of 4.45 and a beta of 1.21.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million during the quarter, compared to analysts’ expectations of $811.17 million. During the same quarter last year, the business posted $0.52 earnings per share. The company’s revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s payout ratio is currently 38.46%.

Analyst Ratings Changes

BRKR has been the subject of a number of recent research reports. Wells Fargo & Company decreased their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the stock a “hold” rating in a research note on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Citigroup decreased their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Finally, Bank of America cut their target price on Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $51.30.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently made changes to their positions in BRKR. Nisa Investment Advisors LLC increased its position in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after buying an additional 487 shares during the period. Pinnacle Bancorp Inc. purchased a new position in shares of Bruker during the first quarter worth approximately $29,000. Allworth Financial LP increased its holdings in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 364 shares during the period. Huntington National Bank raised its position in Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in Bruker during the 2nd quarter worth $32,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.